-
2023-504977-19-00
5
2021-03-15
Moderately to Severely Active Ulcerative Colitis
-
2022-502031-20-00
10
2020-12-17
Non-squamous non-small cell lung cancer (NSCLC)
-
2024-514495-41-00
5
2020-11-04
Primary Progressive Multiple Sclerosis
-
2023-510107-22-00
5
2020-10-27
Hematopoietic stem cell transplant-associated thrombotic microangiopat
-
2023-506610-52-00
5
2020-06-24
Mild or moderate hemophilia A without FVIII inhibitors
-
2023-503600-83-00
5
2020-05-27
Moderate to Severe Plaque Psoriasis
-
2023-503749-76-00
1
2020-03-06
Solid Tumors
-
2023-503382-29-00
5
2020-01-20
Primary Hyperoxaluria Type 1 (PH1)
-
2022-502886-71-00
5
2019-11-20
Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
-
2023-506657-38-00
5
2019-10-02
Biliary Tract Carcinoma
-
2023-505614-17-00
5
2019-09-20
Participants with advanced or recurrent endometrial carcinoma
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2022-502936-38-00
5
2019-01-09
Moderate and Severe Atopic Dermatitis
-
2022-502124-52-00
5
2018-12-18
Advanced epithelial ovarian cancer
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2024-510738-42-00
5
2018-12-03
Haemophilia B
-
2023-510189-28-00
6
2018-05-15
Rheumatoid Arthritis
-
2024-516783-29-00
6
2018-04-16
Severe allergic and eosinophilic asthma
-
2022-500251-22-00
4
2018-04-12
This study will include all patients having received at least one infu
-
2024-517290-24-00
4
2017-12-19
Previously untreated advanced uveal melanoma (UM)
-
2023-509595-42-00
5
2017-10-31
Gastric and gastroesophageal junction (GEJ) adenocarcinoma
-
2023-510557-42-00
4
2017-07-10
chronic lymphocytic leukemia
-
2023-507271-21-00
5
2017-04-11
Follicular Lymphoma
-
2023-508010-42-00
5
2016-09-14
Homologous recombination deficiency advanced ovarian cancer